V-Card | Print | PDF | Email Page

Tamera M. Weisser Ph.D. (Tammy)


(T) +1.858.314.1181
(F) +1.844.345.3178


  • Georgetown University (J.D. 2004); University of Massachusetts Medical School (Ph.D. in Immunology and Virology 2000); University of Wisconsin-Madison (B.S. in Molecular Biology 1993)

Bar Admissions

  • California, U.S. Supreme Court, U.S. District Court for the Southern District of California, U.S. Court of Appeals for the Federal Circuit, and registered to practice before the U.S. Patent and Trademark Office

Dr. Tamera (Tammy) Weisser is co-leader of Jones Day's global patent prosecution group, comprising more than 100 professionals worldwide. She has nearly 20 years of experience in global patent portfolio development, management, and enforcement in biotechnology, particularly in the areas of biologics and diagnostics. For example, on behalf of NGM Biopharmaceuticals, Tammy coordinates the implementation of a global patent strategy concerning novel protein and antibody therapeutics in clinical trials for the treatment of diabetes, NASH (nonalcoholic steatohepatitis), and other metabolic disorders. On behalf of BioMarin, she established a worldwide patent portfolio for Palynziq®, an enzyme replacement therapy recently approved by the FDA for phenylketonuria treatment. She has developed IP strategies for dozens of antibody therapeutics for clients, including Celgene, Kyowa Hakko Kirin, and MedImmune (AstraZeneca). Commercial products for which Tammy has experience include EmboSpheres®, HepaSpheres®, Humira®, Kynamro®, Otezla®, Pomalyst®, Revlimid®, and Synagis®.

Her practice also includes performing patent validity and freedom-to-operate analyses and conducting due diligence of patent portfolios for clients, including potential investors, acquirers, and licensees. She has been involved in numerous oppositions before the European Patent Office as well as interferences.

In addition, Tammy has in-depth experience in inter partes review (IPR) proceedings. She successfully defended AbbVie in two IPRs brought by Amgen, five IPRs brought by Coherus, and another IPR brought by Sandoz in connection with patents related to formulations for AbbVie's antibody adalimumab, marketed as Humira®, in which the PTAB denied institution of each petition.

Tammy served on the board of directors of several local professional organizations, and she is consistently recognized as being a top attorney and for her leadership and contribution within the community.

Honors & Distinctions

  • 2018: "IP Trailblazers," National Law Journal

    2018: "Top Intellectual Property Lawyers in California," The Daily Journal

    2017-2018: "Top Women Lawyers in California," The Daily Journal

    2017: "Most Influential Women in San Diego," The Daily Transcript

    2016-2018: Recommended Lawyer, Legal 500 US

    2016-2018: Super Lawyers, San Diego

    2013: "Women Who Mean Business" Award, San Diego Business Journal

    2012: Athena San Diego Pinnacle Award
Tamera Weisser Tammy